MedTrace Logo

Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial

NCT00717756 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2020-02-17

Study results available
· View outcomes & findings →

Summary

This study will determine whether lenalidomide has activity in patients with advanced liver cancer that have had growth of their cancer after sorafenib.

Conditions

Interventions

DRUG

lenalidomide

25 mg po qd x 21 days then 1 week off equals one cycle

Sponsors & Collaborators

  • Memorial Hospital of Rhode Island

    collaborator OTHER

  • Roger Williams Medical Center

    collaborator OTHER

  • Brown University

    lead OTHER

Principal Investigators

  • Howard Safran, MD · Brown University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-12-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00717756 on ClinicalTrials.gov